Jump Financial LLC Reduces Stake in Castle Biosciences, Inc. (NASDAQ:CSTL)

Posted by Defense World Staff on Aug 8th, 2023

Jump Financial LLC cut its stake in shares of Castle Biosciences, Inc. (NASDAQ:CSTL – Free Report) by 9.8% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 17,400 shares of the company’s stock after selling 1,900 shares during the period. Jump Financial LLC owned 0.07% of Castle Biosciences worth $395,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also modified their holdings of the stock. Mesirow Financial Investment Management Inc. purchased a new stake in Castle Biosciences during the 1st quarter valued at $328,000. Essex Investment Management Co. LLC lifted its holdings in shares of Castle Biosciences by 3.8% in the 4th quarter. Essex Investment Management Co. LLC now owns 453,317 shares of the company’s stock worth $10,671,000 after acquiring an additional 16,682 shares during the last quarter. Isthmus Partners LLC boosted its stake in shares of Castle Biosciences by 2.1% during the 4th quarter. Isthmus Partners LLC now owns 57,812 shares of the company’s stock worth $1,361,000 after purchasing an additional 1,173 shares during the period. Ten Capital Wealth Advisors LLC purchased a new position in shares of Castle Biosciences during the 4th quarter worth about $32,000. Finally, New York State Common Retirement Fund grew its holdings in Castle Biosciences by 4.5% during the 4th quarter. New York State Common Retirement Fund now owns 214,478 shares of the company’s stock valued at $5,049,000 after purchasing an additional 9,244 shares during the last quarter. 82.44% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. Scotiabank decreased their price objective on shares of Castle Biosciences from $54.00 to $33.00 in a research note on Wednesday, June 7th. BTIG Research dropped their price objective on Castle Biosciences from $38.00 to $30.00 in a report on Thursday, June 15th. Lake Street Capital reduced their target price on Castle Biosciences from $41.00 to $32.00 in a research note on Monday, June 5th. KeyCorp decreased their target price on Castle Biosciences from $37.00 to $25.00 and set an “overweight” rating for the company in a research report on Friday. Finally, SVB Securities cut their price target on shares of Castle Biosciences from $50.00 to $35.00 in a report on Monday, June 5th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Castle Biosciences has an average rating of “Buy” and a consensus price target of $34.50.

View Our Latest Report on Castle Biosciences

Castle Biosciences Stock Down 3.3 %

Shares of NASDAQ CSTL opened at $17.89 on Tuesday. Castle Biosciences, Inc. has a twelve month low of $9.26 and a twelve month high of $36.10. The business has a fifty day simple moving average of $16.11 and a two-hundred day simple moving average of $21.13.

Insider Activity

In other Castle Biosciences news, insider Derek J. Maetzold sold 1,538 shares of the stock in a transaction dated Monday, May 15th. The shares were sold at an average price of $23.45, for a total transaction of $36,066.10. Following the transaction, the insider now directly owns 150,443 shares in the company, valued at approximately $3,527,888.35. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Castle Biosciences news, insider Derek J. Maetzold sold 1,538 shares of the company’s stock in a transaction on Monday, May 15th. The stock was sold at an average price of $23.45, for a total transaction of $36,066.10. Following the completion of the sale, the insider now owns 150,443 shares in the company, valued at $3,527,888.35. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Ellen Goldberg bought 4,800 shares of the company’s stock in a transaction on Monday, June 5th. The shares were bought at an average cost of $14.38 per share, for a total transaction of $69,024.00. Following the transaction, the director now directly owns 9,065 shares in the company, valued at approximately $130,354.70. The disclosure for this purchase can be found here. Over the last 90 days, insiders have sold 60,200 shares of company stock worth $1,229,170. Company insiders own 7.70% of the company’s stock.

About Castle Biosciences

(Free Report)

Castle Biosciences, Inc, a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma.